Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA

3 days ago 4

Talha Qureshi

Mon, November 17, 2025 astatine 11:15 AM CST 2 min read

uniQure N.V. (NASDAQ:QURE) is 1 of the Hottest Small Cap Stocks to Buy Now. Wall Street has a affirmative outlook connected uniQure N.V. (NASDAQ:QURE) contempt the regulatory challenges from the FDA for its experimental cistron therapy called AMT-130. On November 12, Yanan Zhu from Wells Fargo besides reiterated a Buy standing connected uniQure N.V. (NASDAQ:QURE), but lowered the terms people from $80 to $60. A time earlier, TD Cowen expert Joseph Thome had maintained a Buy standing connected the banal without disclosing immoderate terms target.

Earlier successful September, uniQure N.V. (NASDAQ:QURE) presented captious results from a three-year survey of their experimental cistron therapy called AMT-130, aimed astatine treating Huntington’s disease. The results showed a important simplification successful illness progression.

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

However, careless of the encouraging results, the FDA connected November 3 provided antagonistic feedback for AMT-130. As per the management, the FDA nary longer thinks the information from their aboriginal Phase I/II studies of AMT-130 is capable to enactment their main grounds for getting support to merchantability the therapy. As a result, the timing for the pre-Biologics License Application for AMT-130 is present unclear.

Analyst Joseph Thome from TD Cowen noted that management’s assurance successful the information and imaginable of AMT-130 remains robust. He mentioned the institution is successful progressive engagement with the FDA to research a viable mode forward. Thome remains assured successful the company’s quality to code these concerns effectively.

uniQure N.V. (NASDAQ:QURE) is simply a biotechnology institution based successful the Netherlands that develops cistron therapies designed to beryllium fixed erstwhile and perchance cure terrible familial diseases.

While we admit the imaginable of QURE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.